戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 er 16 patients (61+/-8 years, 1 female) were randomized.
2 gnosed at US were prospectively enrolled and randomized.
3 ptember 17, 2014, and November 18, 2015, and randomized 1:1 in a masked fashion to receive bevacizuma
4 ron therapy) patients without cirrhosis were randomized 1:1 to receive 12 or 16 weeks of G/P (300 mg/
5                          Forty patients were randomized 1:1 to treatment with serelaxin intravenous (
6        METHODS AND In Bangladesh, we cluster-randomized (1:1) 142 villages of the Matlab Health and D
7 tinine <1.2 mg/dL, and normoalbuminuria were randomized (1:1) with permuted blocks to 6 months of a 2
8 0) enrolled infants born to women previously randomized (1:1:1:1) to receive either GBS vaccine at do
9 s (interquartile range, 3.0-8.0 months) were randomized; 110 children were placed in the EHCF group,
10                               METHODS AND We randomized 12 subjects with heart failure with preserved
11 x, 65.8%) were mite sensitized, and 284 were randomized (146 to the active group and 138 to the place
12                                  The authors randomized 150 patients with advanced HF between August
13                                           We randomized 156 adult subjects undergoing cardiac surgery
14                                              Randomized 2 x 2 factorial clinical trial in neonates (>
15 is In Myocardial Infarction 54) trial, which randomized 21,162 patients to ASA alone, ticagrelor 60 m
16                 A total of 494 patients were randomized, 25 did not meet the criteria and 469 were an
17 ected Coronary Artery Disease) prospectively randomized 350 patients with stable angina (55% women; a
18                                           We randomized 54 stable outpatients with cirrhosis and asci
19                              VISTA and VIVID randomized 872 DME patients to receive intravitreal afli
20                                           We randomized 960 participants in 120 peer educator groups
21                                              Randomized and nonrandomized comparative studies that en
22                               Initially, 157 randomized and nonrandomized studies on therapies (syste
23                 A total of 267 patients were randomized, and the study arms were well matched at base
24                                              Randomized, assessor-blinded, single-center study within
25 nse to egg white (EW) of less than 2 mm were randomized at age 4 months to receive whole-egg powder o
26                   METHODS AND We performed a randomized (at patient level, blocks of 4), controlled n
27                              Out of the five randomized bases, a 5' thymidine is present in most of t
28  now, qubits have been assessed primarily by randomized benchmarking, which reports a different error
29 esophageal junction tumors (Siewert I), were randomized between open and MI esophagectomy with curati
30     Using block randomization, patients were randomized between oral study medication and CBT (2:1) f
31                                BENEFIT was a randomized clinical trial comparing early versus delayed
32                                              Randomized clinical trial conducted at 2 urban EDs in th
33                                         This randomized clinical trial demonstrated better postoperat
34 -masked, parallel-group, placebo-controlled, randomized clinical trial included 117 patients with pla
35 loratory analysis of secondary outcomes of a randomized clinical trial of extremely preterm infants,
36                           Four-group cluster randomized clinical trial of mothers of healthy term new
37                   In this 2-year, follow-up, randomized clinical trial of patients with Duchenne or B
38 itute (NCI) sponsored, multicenter, phase 3, randomized clinical trial open to patients with biopsy-p
39 xploratory analysis of the multicenter FinXX randomized clinical trial that accrued 1500 women in Fin
40                                            A randomized clinical trial was conducted from February 1
41         A double-blinded, placebo-controlled randomized clinical trial was conducted from October 1,
42 different breast cancer subtypes in a large, randomized clinical trial with long-term follow-up.
43                                      In this randomized clinical trial, 268 active-duty servicemember
44      In this secondary analysis of a phase 3 randomized clinical trial, a low level of preexisting cy
45 y, including 9 retrospective reports and one randomized clinical trial, and five retrospective studie
46          This parallel-design, double-blind, randomized clinical trial, called Resveratrol to Improve
47                   In this 2-group, parallel, randomized clinical trial, including a nonrandomized obs
48                        In this substudy of a randomized clinical trial, study eyes of subjects assign
49                        A multicenter phase 2 randomized clinical trial, the Arginine Deiminase and Me
50 t of Acute Cerebral Hemorrhage II (ATACH-II) randomized clinical trial.
51                             English-language randomized clinical trials (RCTs) or prospective cohort
52                                  We included randomized clinical trials and prospective observational
53 kin) may improve vascular diseases; however, randomized clinical trials are needed to confirm these f
54                      The lack of prospective randomized clinical trials demonstrating that full-body
55       An initial meta-analysis identified 14 randomized clinical trials for treatment of mNSCLC with
56                                              Randomized clinical trials in which self-guided iCBT was
57                                         Four randomized clinical trials met the selection criteria an
58 orts use of PB-MRD as a primary end point in randomized clinical trials of chemoimmunotherapy in CLL.
59 and BCL6 translocations in two prospectively randomized clinical trials of patients with diffuse larg
60 tional meta-analysis and create a network of randomized clinical trials to compare outcomes after spe
61  this area are conflicting, and there are no randomized clinical trials to guide practitioner decisio
62 ow how Bayesian analysis takes evidence from randomized clinical trials to update what is already kno
63                    Results From 109 included randomized clinical trials, 108 ASCOv1, 111 ASCOv2, and
64 y reviewed and selected studies if they were randomized clinical trials, included adults hospitalized
65 we sought systematic reviews, meta-analyses, randomized clinical trials, prospective comparative obse
66 wering treatment can be established only via randomized clinical trials.
67                                  Single site randomized control trial, 3 groupsx4 time points mixed f
68 richment (biomarker-positive patients) and a randomized controlled design by pre-approval trials and
69                                          The randomized controlled Mycotic Ulcer Treatment Trial (MUT
70  systematic review was conducted to identify randomized controlled studies comparing nurse-led self-m
71 s in both members of the dyad.We conducted a randomized controlled study of 97 mother-infant dyads.
72                                         This randomized controlled trial examined the efficacy of a n
73                               We conducted a randomized controlled trial of AF screening using an Ali
74               We studied participants from a randomized controlled trial of primary prevention with s
75                   We conducted a prospective randomized controlled trial to study the impact of in-ho
76                  We performed a parallel-arm randomized controlled trial to test whether administrati
77 ate Cancer: Evaluation of Drug Efficacy is a randomized controlled trial using a multiarm, multistage
78 ial multiple-assignment randomized trial (or randomized controlled trial) may be inadequate.
79                                      In this randomized controlled trial, 128 young adults (71 male,
80 n (WS) and the risk of weight regain.In this randomized controlled trial, 61 healthy overweight or ob
81                                        Quasi-randomized controlled trial.
82      Prospective, single-center, nonblinded, randomized controlled trial.
83                                        While randomized controlled trials (RCTs) are based on strict
84 hed PubMed, EMBASE, and PsycINFO to identify randomized controlled trials (RCTs), meta-analyses, and
85 ions retrieved, 42 met inclusion criteria (5 randomized controlled trials and 37 observational studie
86         This study sets the stage for larger randomized controlled trials and testing in other emotio
87                                              Randomized controlled trials are required to confirm the
88                            Further data from randomized controlled trials are urgently needed because
89         We searched electronic databases for randomized controlled trials comparing AL to non-ACTs th
90 literature review and identified more recent randomized controlled trials comparing dose-escalated ex
91       Two reviewers independently identified randomized controlled trials comparing dynamic assessmen
92 tion of FA and focuses on recently published randomized controlled trials exploring the efficacy of o
93                                              Randomized controlled trials have demonstrated that the
94 INAHL, and CENTRAL through July 1, 2016, for randomized controlled trials of CCT in older adults with
95                                         Most randomized controlled trials of routine versus selective
96                     RATIONALE: Single-center randomized controlled trials of the Zephyr endobronchial
97                         Assessing surgery in randomized controlled trials raises several challenges.
98       Hence, authors and journals publishing randomized controlled trials should pay attention that s
99                                 In total, 17 randomized controlled trials were identified, including
100                                 Twenty-three randomized controlled trials with 2,751 patients were in
101 yndrome (ARDS) subphenotypes in two separate randomized controlled trials with differential response
102   Rigorous double-blind, placebo-controlled, randomized controlled trials, using commonly available o
103                  We performed a prospective, randomized, controlled trial in nondiabetic DIOS patient
104                           This double-blind, randomized, controlled trial investigates the effects of
105                                         In a randomized, controlled trial that compared liraglutide,
106 ouraging preliminary results, we conducted a randomized, controlled trial to determine whether minocy
107                            We present here a randomized, controlled trial using allogeneic MSC, which
108 se recommendations on a systematic review of randomized, controlled trials and systematic reviews pub
109  from professional societies supplemented by randomized, controlled trials; meta-analyses; and system
110                 TRANSGRIPE 1-2 is a phase 3, randomized, controlled, multicenter, open-label clinical
111 ducted two parallel, pragmatic, multicenter, randomized, controlled, open-label trials with blinded o
112  placebo over 2 test days in a double-blind, randomized, counterbalanced, cross-over design.
113                               A single-blind randomized crossover design was used.
114                       This was a prospective randomized crossover study in nonintubated patients with
115                                         In a randomized double-blind placebo-controlled study, 56 pat
116     Four hundred forty-six CAE children in a randomized double-blind trial of ethosuximide, lamotrigi
117 label study including 12 patients; a phase 3 randomized, double blind, placebo controlled study invol
118 he field treatment of actinic keratosis in a randomized, double-blind clinical trial involving 131 pa
119          Purpose LUME-Meso is a phase II/III randomized, double-blind trial designed to assess effica
120                                            A randomized, double-blind, multisite placebo-controlled t
121                                      In this randomized, double-blind, phase 3 study, we assigned 339
122                                             (Randomized, Double-Blind, Placebo Controlled Study of th
123                                         In a randomized, double-blind, placebo-controlled crossover s
124 omical brain magnetic resonance imaging to a randomized, double-blind, placebo-controlled trial (RCT)
125                                         This randomized, double-blind, placebo-controlled trial asses
126                       METHODS AND TIME was a randomized, double-blind, placebo-controlled trial compa
127                      We conducted a phase 2, randomized, double-blind, placebo-controlled trial in 27
128                         METHOD: This 6-week, randomized, double-blind, placebo-controlled trial inclu
129 Antidepressant Sertraline Trial (CAST) was a randomized, double-blind, placebo-controlled trial invol
130                               We conducted a randomized, double-blind, placebo-controlled trial of am
131            In this prospective, multicenter, randomized, double-blind, placebo-controlled trial, 96 H
132                      We conducted a phase I, randomized, double-blind, placebo-controlled, dose-escal
133                                         This randomized, double-blind, placebo-controlled, multicente
134                         In this multicenter, randomized, double-blind, placebo-controlled, parallel-g
135 rea in an African Region with Malaria) was a randomized, double-blinded, placebo-controlled trial con
136                                  In 2 large, randomized, double-masked trials reported here, once-dai
137                      Twelve-week, phase III, randomized, double-masked, multicenter, placebo-controll
138 id macular edema (PCME) using a prospective, randomized, double-masked, placebo-controlled clinical s
139                     Thirty-two patients were randomized equally into 2 treatment arms (control and in
140 ondary analysis of prospective data from the Randomized Evaluation of Sedation Titration for Respirat
141 lysis of data from the 36-month prospective, randomized, FAME A and B trials.
142                                Patients were randomized in a 1:1 fashion and stratified according to
143 acutely medically ill subjects (n=7513) were randomized in a double-dummy double-blind fashion to eit
144 m 401 patients enrolled in the international randomized International Extranodal Lymphoma Study Group
145 agmatic, general practitioner-based, cluster-randomized intervention trial compared the intervention
146 al acuity (VA) assessor-masked, multicenter, randomized, interventional study.
147 mplications requiring PPV were prospectively randomized into 1 of 2 treatment groups: Group A receive
148                            Participants were randomized into 2 incubations arms, either 10-minute or
149 l data from 2092 patients with enteric fever randomized into 4 trials in Kathmandu, Nepal, were poole
150 genation emergency (Sim1-recirculation) then randomized into simulation and traditional groups.
151 udy consisting of 1 screening and 2 separate randomized-masked ITN treatments (sham extranasal or int
152                          Of the 721 patients randomized (mean [SD] age, 61.4 [10.5] years; 53.1% male
153              Among the 925 patients who were randomized (mean [SD] age, 9.7 [5.3] years; 575 males [6
154     Of 361 children and adolescents who were randomized (mean [SD] age, 9.8 [3.2] years; 38% female;
155 ts and continued metformin in the originally randomized metformin group.
156                             This prospective randomized multicenter trial provides evidence that clin
157  We analyzed individual patient data from 13 randomized multicenter trials of induction and maintenan
158 nce Performance in Dialysis trial, a 6-month randomized, multicenter trial to test whether a simple,
159                                 Prospective, randomized, multicenter, controlled clinical trial.
160                      This was a prospective, randomized, multicenter, single-blinded trial.
161                           To pilot a cluster-randomized, multiple-crossover trial using software tool
162                                         This randomized noncomparative design allowed safety evaluati
163                               Double-masked, randomized noninferiority clinical trials: Rho Kinase El
164               12-week, single-blind, 3-group randomized noninferiority trial and subsequent 40-week m
165                      We performed a blinded, randomized, noninferiority trial comparing iodine povacr
166 fined as an HRSD17 of 7 following 8 weeks of randomized open-label treatment ADMs: escitalopram, sert
167  single-center, parallel-group, prospective, randomized, open-label, blinded end point trial, consent
168  ms; control protocol) on separate days in a randomized order.
169                               We performed a randomized, parallel, single-blind dose-ranging phase 2
170                                     Phase 2, randomized, parallel-group, dosage-finding, 26-week tria
171  board-approved, single-center, prospective, randomized, parallel-group, open-label treatment trial w
172                 We conducted a double-blind, randomized, parallel-group, placebo-controlled trial of
173                                Among the 136 randomized participants (mean age, 50.4 [SD, 13.3] years
174                                    Among 480 randomized participants, 465 (97%) were included in the
175                                    Of the 50 randomized participants, 49 (98%) received all 3 lamotri
176                                    Among 477 randomized patients (mean age, 44 years [SD, 15]; women,
177                                    Among 336 randomized patients (mean age, 68 years; 16% women), 333
178                                    Among 401 randomized patients, 2 withdrew immediately after random
179                                       Of 722 randomized patients, 552 had cytogenetic results; 137 (2
180                                  Of the 2032 randomized patients, baseline health status was availabl
181 cted a prospective, multicenter, open-label, randomized phase III trial that compared a busulfan-base
182                                 Prospective, randomized, pilot study.
183 A38 patients, and carried out a double-blind randomized placebo-controlled study for 16 weeks, follow
184                          We thus performed a randomized placebo-controlled trial with atorvastatin 40
185      Therefore, we conducted a double-blind, randomized, placebo-controlled crossover trial in 18 adu
186           In this multicenter, double-blind, randomized, placebo-controlled study, 74 participants wi
187 per DSM-IV-TR criteria were enrolled in this randomized, placebo-controlled trial consisting of an in
188           In this multicenter, double-blind, randomized, placebo-controlled trial, we assessed the ef
189 ame as those found in all four much smaller, randomized, placebo-controlled trials specifically desig
190                        Using a double-blind, randomized, placebo-controlled, parallel design, we test
191                        In this double-blind, randomized, placebo-controlled, phase 2 trial, we assign
192                               We initiated a randomized, placebo-controlled, phase 3 trial of the chi
193 omly to the Strong African American Families randomized prevention trial or to a control condition.
194                                         In a randomized prospective trial, the imaging modalities wer
195                                 Multicenter, randomized, prospective, single-masked trial.
196 ondary analysis of data from the prospective randomized Recompensation of Exacerbated Liver Insuffici
197                                              Randomized, single-masked, controlled trial.
198  not reduce 28-day/hospital mortality in the randomized studies (relative risk, 0.93; 95% CI, 0.77-1.
199 intervention in type 2 diabetes, but further randomized studies are warranted.
200 tle-Ottawa Scale and the Risk of Bias in Non-randomized Studies of Interventions tool, respectively.
201     Inclusion criteria were observational or randomized studies of septic patients, evaluation of ant
202                    In total, 32 eligible non-randomized studies with 4697 patients (LLR: 1809, OLR: 2
203                          The ERSPC (European Randomized Study of Screening for Prostate Cancer) found
204 s, we demonstrate that an approach of local, randomized tailoring of bond stiffness via microalloying
205                Peer educator-FSW groups were randomized to 1 of 3 arms: (1) delivery (direct distribu
206                               Female smokers randomized to 21 mg nicotine (TNP; n=37) or placebo (PBO
207          All participants were implanted and randomized to a paired VNS (n = 16) or control (n = 14)
208          Sixty healthy adult volunteers were randomized to a single standard, autologous, leukoreduce
209 s board approval, second year residents were randomized to a teaching intervention targeting cognitiv
210  with HER2-positive metastatic breast cancer randomized to an antibody-based (trastuzumab) vs a small
211 y-eight communities in Matameye, Niger, were randomized to annual oral azithromycin treatment of the
212       Thirty pigs were anesthetized and then randomized to cardiac arrest induced by three diffrent m
213                                Patients were randomized to either an NT-proBNP-guided strategy or usu
214 d an emphysematous appearance, patients were randomized to either standard management or intervention
215                                     Patients randomized to etelcalcetide were significantly more like
216                 During year 1, patients were randomized to evolocumab, 420 mg, plus standard of care
217 rch 8, 2012, to September 23, 2014, and were randomized to group or individual CPT.
218                            Participants were randomized to one of the following study arms: view a on
219 o thrombus aspiration and 262 of 9151 (2.9%) randomized to PCI alone (hazard ratio, 0.84; 95% confide
220                                Only patients randomized to placebo were considered.
221 -volume pancreas centers were preoperatively randomized to placement of a drain or no drain.
222 mary percutaneous coronary intervention were randomized to prasugrel or ticagrelor with an intended t
223 wing percutaneous coronary intervention were randomized to ranolazine versus placebo.
224                       Eligible children were randomized to ready-made or custom-made spectacles.
225 ty patients not eligible for adalimumab were randomized to receive 12 weeks of blind treatment with p
226   Three hundred forty-nine participants were randomized to receive 2000 IU/d of vitamin D oral supple
227          Healthy, HIV-uninfected adults were randomized to receive 4 mg of PENNVAX-G DNA delivered in
228 igh-dose group) vs 354 participants who were randomized to receive 400 IU/d (standard-dose group) for
229 participants 65 years or older with PAD were randomized to receive a daily capsule of resveratrol, 12
230                                Patients were randomized to receive concurrent pyridoxine (200 mg) or
231 ticipants with allergic rhinitis (n=42) were randomized to receive eight weekly doses of i.n.
232 agia and active esophageal eosinophilia were randomized to receive either BOS 2 mg or placebo twice d
233           Adults/adolescents (N = 1071) were randomized to receive either omalizumab (n = 542) or pla
234                 Six healthy adult males were randomized to receive either single daily 80 mg doses of
235  recruited for this study; 270 patients were randomized to receive eravacycline, and 271 patients wer
236  receive eravacycline, and 271 patients were randomized to receive ertapenem.
237 al, 401 participants aged 6 to 11 years were randomized to receive once-daily tiotropium 5 mug (2 puf
238 rom community groups, 5110 participants were randomized to receive vitamin D3 (n = 2558) or placebo (
239                                Patients were randomized to robotic-assisted (n = 237) or conventional
240 mcitabine-based chemotherapy had failed were randomized to selumetinib plus MK-2206 or mFOLFOX.
241 Disease (MDRD) Trial participants previously randomized to strict versus usual BP control.
242 ge] age, 12.9 [11.2-15.3]), of whom 684 were randomized to the control group and 685 to the intervent
243  months; 468 [60.2%] male), 385 (49.5%) were randomized to the HS group and 387 (49.8%) to the NS gro
244 7.8 kg; mean months post partum, 5.2 months) randomized to the intervention group (n = 174) or standa
245                                Patients were randomized to the liberal (hemoglobin threshold, < 9 g/d
246                  A total of 52 patients were randomized to the rotating arm (median [range] age, 65 [
247 days occurred in 221 of 9155 patients (2.4%) randomized to thrombus aspiration and 262 of 9151 (2.9%)
248       In a double-blind trial, patients were randomized to tolvaptan 30 mg/day or placebo.
249 al artery stenotic or occlusive lesions were randomized to treatment with plain balloon angioplasty (
250                                Patients were randomized to TTM (33 +/- 1 degrees C) for 48 hours (n =
251                                     Patients randomized to UC + PAL versus UC alone had clinically si
252 rgoing PM for Stage 0-III breast cancer were randomized to undergo either standard PM ("no shave", n
253 cebo-controlled trial, 96 HT recipients were randomized to undergo ramipril or placebo therapy.
254                            Participants were randomized to vitamin E, selenium, vitamin E and seleniu
255 thy male subjects (n=29) participated in two randomized treatment periods of daily placebo or PF-0495
256           Eighty-five patients completed the randomized treatment phases.
257             Multicenter, placebo-controlled, randomized trial (July 2013 to final follow-up October 2
258  include in a sequential multiple-assignment randomized trial (or randomized controlled trial) may be
259                                     Within a randomized trial designed to examine nonspecific effects
260                            This prospective, randomized trial found that treat and extend dosing of r
261           This was a multicenter prospective randomized trial including 143 patients with moderate-se
262                                            A randomized trial is needed.
263                       We conducted the first randomized trial of behavioral weight loss for HIV-infec
264                                FOURIER was a randomized trial of evolocumab versus placebo in 27 564
265                                In a phase 2B randomized trial of patients with moderate to severe DG,
266         To our knowledge, this was the first randomized trial to evaluate addition of an oncolytic vi
267             A prospective, international 1:1 randomized trial was conducted to evaluate in a noninfer
268                                         This randomized trial was done to assess effectiveness of PRF
269                             This multicenter randomized trial with 2 parallel arms (drain vs no drain
270 mally invasive esophagectomy, a multicenter, randomized trial).
271                  METHODS AND In this cluster-randomized trial, 10 primary health facilities in the ci
272                                          One randomized trial, 3 quasi-experimental studies, and 40 o
273 Program (RAISE-ETP) study, a 34-site cluster-randomized trial, compared NAVIGATE, a coordinated speci
274                      In a recently published randomized trial, compared with intensified treatment of
275 nemic.In this 2 x 2 factorial, double-blind, randomized trial, nonpregnant women (aged 18-45 y) with
276                                      In this randomized trial, off-pump CABG led to lower rates of 5-
277                                      In this randomized trial, the routine use of pasireotide signifi
278 h neurocognitive effects in a recent phase 3 randomized trial.
279 =0.75 g/dl over any 4-week period during the randomized trial; 57 [48.7%] versus 17 [14.8%] with plac
280  the era of drug-eluting stents, large-scale randomized trials and all-comer registries have shown ex
281                    More convincing data from randomized trials are required to inform the management
282                                              Randomized trials evaluating treatment levels significan
283                                              Randomized trials have demonstrated increased morbidity
284                                         In 2 randomized trials in Guinea-Bissau of early BCG-Denmark
285 were combined for borderline personality and randomized trials in PubMed, PsycINFO, EMBASE, and the C
286 ata meta-analysis of three large prospective randomized trials in which sorafenib was the control arm
287 of studies of de-escalation of BMAs, and two randomized trials of BMAs in control of pain secondary t
288                     Recent meta-analyses and randomized trials on secondary prevention of squamous ce
289                                  METHODS AND Randomized trials reporting clinical outcomes beyond 1 y
290                                              Randomized trials support the use of transcatheter aorti
291          English-language cohort studies and randomized trials that compared different doses of nalox
292                                              Randomized trials that reported pain, function, or harms
293            These findings support conducting randomized trials to explore risks and benefits of OAT r
294 ous double-blind, placebo-controlled cluster-randomized trials were revisited at age 8 y between Febr
295                                              Randomized trials with >/=50 patients, that had exclusiv
296        Constitutive Shisa2 expression causes randomized turning of post-crossing commissural axons al
297                    One hundred patients were randomized with 96 completing the study (150 mL/min, n =
298 open-label period and a 26-week double-blind randomized withdrawal period.
299 , phase 3, double-blind, placebo-controlled, randomized withdrawal study including 418 participants w
300                      We conducted a phase 3, randomized withdrawal, multicenter, placebo-controlled,

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top